207 related articles for article (PubMed ID: 25929323)
1. Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance.
Zhang J; Dong J; Yang Z; Ma X; Zhang J; Li M; Chen Y; Ding Y; Li K; Zhang Z
World J Surg Oncol; 2015 May; 13():168. PubMed ID: 25929323
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
Matsubayashi S; Nakashima M; Kumagai K; Egashira M; Naruke Y; Kondo H; Hayashi T; Shindo H
Pathol Res Pract; 2009; 205(9):626-33. PubMed ID: 19324500
[TBL] [Abstract][Full Text] [Related]
3. Factors Affecting the Recurrence of Giant Cell Tumor of Bone After Surgery: A Clinicopathological Study of 80 Cases from a Single Center.
Cheng DD; Hu T; Zhang HZ; Huang J; Yang QC
Cell Physiol Biochem; 2015; 36(5):1961-70. PubMed ID: 26202356
[TBL] [Abstract][Full Text] [Related]
4. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone.
Li D; Zhang J; Li Y; Xia J; Yang Y; Ren M; Liao Y; Yu S; Li X; Shen Y; Zhang Y; Yang Z
World J Surg Oncol; 2016 Apr; 14():114. PubMed ID: 27094617
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone.
Mosakhani N; Pazzaglia L; Benassi MS; Borze I; Quattrini I; Picci P; Knuutila S
Histol Histopathol; 2013 May; 28(5):671-8. PubMed ID: 23172052
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53 protein expression in giant cell tumor of bone.
Yalcinkaya U; Ugras N; Kabul S; Ocakoglu G; Bilgen MS
Pol J Pathol; 2015 Dec; 66(4):389-96. PubMed ID: 27003771
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.
Mu Y; Zhang H; Che L; Li K
Med Oncol; 2014 Feb; 31(2):821. PubMed ID: 24352761
[TBL] [Abstract][Full Text] [Related]
9. [Relationship of ezrin protein expression to the carcinogenesis and prognosis of infitrating breast ductal carcinoma].
Ma L; Zhang XH; Xing LX; Li YH; Wang XL; Wang YJ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):279-83. PubMed ID: 18788632
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
11. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E; Peres SV; Morini S; de Camargo B
J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
[TBL] [Abstract][Full Text] [Related]
12. Significance of β-catenin expression for the incidence of pathological fractures in giant cell tumors of bone.
Sopta J; Lujic N; Kovacevic R; Davidovic R
Pol J Pathol; 2016; 67(4):345-350. PubMed ID: 28547961
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.
Balla P; Maros ME; Barna G; Antal I; Papp G; Sapi Z; Athanasou NA; Benassi MS; Picci P; Krenacs T
PLoS One; 2015; 10(5):e0125316. PubMed ID: 25933380
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67.
Lujic N; Sopta J; Kovacevic R; Stevanovic V; Davidovic R
Int Orthop; 2016 Nov; 40(11):2393-2399. PubMed ID: 27658412
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study.
Quattrini I; Pollino S; Pazzaglia L; Conti A; Novello C; Ferrari C; Pignotti E; Picci P; Benassi MS
J Orthop Res; 2015 Aug; 33(8):1205-11. PubMed ID: 25764026
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis.
Lieveld M; Bodson E; De Boeck G; Nouman B; Cleton-Jansen AM; Korsching E; Benassi MS; Picci P; Sys G; Poffyn B; Athanasou NA; Hogendoorn PC; Forsyth RG
Virchows Arch; 2014 Dec; 465(6):703-13. PubMed ID: 25304290
[TBL] [Abstract][Full Text] [Related]
17. Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma.
Feleke M; Feng W; Song D; Li H; Rothzerg E; Wei Q; Kõks S; Wood D; Liu Y; Xu J
Exp Biol Med (Maywood); 2022 Jul; 247(14):1214-1227. PubMed ID: 35695550
[No Abstract] [Full Text] [Related]
18. [Expression of ezrin and CD44-v6 in human esophageal squamous cell carcinoma and its clinical significance].
Chai LX; Sun KL; Guo LP; Zhang HT; Lu SX
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):685-8. PubMed ID: 18246799
[TBL] [Abstract][Full Text] [Related]
19. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
20. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
